Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery

Potential role for K+(ATP) channels

Linda M. Gambone, Paul A. Murray, Nicholas Flavahan

Research output: Contribution to journalArticle

Abstract

1. The aim of the present study was to assess interactions between nitric oxide (NO) and prostacyclin (PGI2) during endothelium-dependent relaxations evoked by bradykinin, calcium ionophore (A23187) and acetylcholine in canine isolated pulmonary artery. 2. Relaxations to low concentrations of bradykinin and A23187 were abolished by combined inhibition of NO-synthase (by N(ω)-nitro-L-arginine methyl ester L-NAME, 30 μM) and cyclo-oxygenase (indomethacin, 10 μM), suggesting mediation by NO and PGI2. The individual contributions of NO and PGI2 to the dilator responses were quantified by use of areas above the separate indomethacin-insensitive and L-NAME-insensitive components of the concentration-effect curves, respectively. Individually, NO and PGI2 accounted for only 53 ± 5% and 16 ± 9% of total bradykinin-induced relaxation, and 46 ± 10% and 20 ± 9% of total A23187-induced relaxation, suggesting that NO and PGI2 acted synergistically to cause endothelium-dependent relaxation. 3. Relaxation to low concentrations of acetylcholine was abolished by L-NAME but not affected by indomethacin, suggesting the response was mediated solely by NO with no interaction from PGI2. 4. Glibenclamide (1 μM), an inhibitor of ATP-sensitive potassium (K+A(ATP)) channels, inhibited responses to bradykinin or A23187 but did not affect relaxations evoked by acetylcholine. Glibenclamide did not affect endothelium-independent relaxations to PGI2 or the NO-donor, 3-morpholinosydnonimine (SIN-1). 5. With bradykinin, glibenclamide attenuated total relaxation by 49 ± 8%, but did not alter the individual NO and PGI2-mediated components of the response. Glibenclamide abolished the synergistic interaction between endothelium-derived NO and PGI2. 6. At high concentrations, bradykinin, A23187 or acetylcholine caused endothelium-dependent relaxation that was insensitive to L-NAME + indomethacin. With bradykinin or A23187, this component of relaxation was inhibited by glibenclamide, whereas with acetylcholine, glibenclamide had no effect. 7. The synergistic interaction between endothelium-derived NO and PGI2 in canine pulmonary artery is mediated by activation of K+(ATP) channels, presumably by an endothelium-derived hyperpolarizing factor (EDHF). The pattern of endothelial dilator mediators and the presence of this synergistic interaction is dependent on the nature of the endothelial stimulus.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalBritish Journal of Pharmacology
Volume121
Issue number2
StatePublished - 1997

Fingerprint

Epoprostenol
Pulmonary Artery
Nitric Oxide
Adenosine Triphosphate
Bradykinin
Glyburide
Calcimycin
Acetylcholine
Endothelium
NG-Nitroarginine Methyl Ester
Indomethacin
Canidae
Nitric Oxide Donors
Calcium Ionophores
Prostaglandin-Endoperoxide Synthases
Nitric Oxide Synthase
Potassium

Keywords

  • A23187
  • Acetylcholine
  • Bradykinin
  • EDHF
  • Indomethacin
  • L-NAME

ASJC Scopus subject areas

  • Pharmacology

Cite this

Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery : Potential role for K+(ATP) channels. / Gambone, Linda M.; Murray, Paul A.; Flavahan, Nicholas.

In: British Journal of Pharmacology, Vol. 121, No. 2, 1997, p. 271-279.

Research output: Contribution to journalArticle

@article{43e40a7198d1406b805d3edd4ac89bb6,
title = "Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery: Potential role for K+(ATP) channels",
abstract = "1. The aim of the present study was to assess interactions between nitric oxide (NO) and prostacyclin (PGI2) during endothelium-dependent relaxations evoked by bradykinin, calcium ionophore (A23187) and acetylcholine in canine isolated pulmonary artery. 2. Relaxations to low concentrations of bradykinin and A23187 were abolished by combined inhibition of NO-synthase (by N(ω)-nitro-L-arginine methyl ester L-NAME, 30 μM) and cyclo-oxygenase (indomethacin, 10 μM), suggesting mediation by NO and PGI2. The individual contributions of NO and PGI2 to the dilator responses were quantified by use of areas above the separate indomethacin-insensitive and L-NAME-insensitive components of the concentration-effect curves, respectively. Individually, NO and PGI2 accounted for only 53 ± 5{\%} and 16 ± 9{\%} of total bradykinin-induced relaxation, and 46 ± 10{\%} and 20 ± 9{\%} of total A23187-induced relaxation, suggesting that NO and PGI2 acted synergistically to cause endothelium-dependent relaxation. 3. Relaxation to low concentrations of acetylcholine was abolished by L-NAME but not affected by indomethacin, suggesting the response was mediated solely by NO with no interaction from PGI2. 4. Glibenclamide (1 μM), an inhibitor of ATP-sensitive potassium (K+A(ATP)) channels, inhibited responses to bradykinin or A23187 but did not affect relaxations evoked by acetylcholine. Glibenclamide did not affect endothelium-independent relaxations to PGI2 or the NO-donor, 3-morpholinosydnonimine (SIN-1). 5. With bradykinin, glibenclamide attenuated total relaxation by 49 ± 8{\%}, but did not alter the individual NO and PGI2-mediated components of the response. Glibenclamide abolished the synergistic interaction between endothelium-derived NO and PGI2. 6. At high concentrations, bradykinin, A23187 or acetylcholine caused endothelium-dependent relaxation that was insensitive to L-NAME + indomethacin. With bradykinin or A23187, this component of relaxation was inhibited by glibenclamide, whereas with acetylcholine, glibenclamide had no effect. 7. The synergistic interaction between endothelium-derived NO and PGI2 in canine pulmonary artery is mediated by activation of K+(ATP) channels, presumably by an endothelium-derived hyperpolarizing factor (EDHF). The pattern of endothelial dilator mediators and the presence of this synergistic interaction is dependent on the nature of the endothelial stimulus.",
keywords = "A23187, Acetylcholine, Bradykinin, EDHF, Indomethacin, L-NAME",
author = "Gambone, {Linda M.} and Murray, {Paul A.} and Nicholas Flavahan",
year = "1997",
language = "English (US)",
volume = "121",
pages = "271--279",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery

T2 - Potential role for K+(ATP) channels

AU - Gambone, Linda M.

AU - Murray, Paul A.

AU - Flavahan, Nicholas

PY - 1997

Y1 - 1997

N2 - 1. The aim of the present study was to assess interactions between nitric oxide (NO) and prostacyclin (PGI2) during endothelium-dependent relaxations evoked by bradykinin, calcium ionophore (A23187) and acetylcholine in canine isolated pulmonary artery. 2. Relaxations to low concentrations of bradykinin and A23187 were abolished by combined inhibition of NO-synthase (by N(ω)-nitro-L-arginine methyl ester L-NAME, 30 μM) and cyclo-oxygenase (indomethacin, 10 μM), suggesting mediation by NO and PGI2. The individual contributions of NO and PGI2 to the dilator responses were quantified by use of areas above the separate indomethacin-insensitive and L-NAME-insensitive components of the concentration-effect curves, respectively. Individually, NO and PGI2 accounted for only 53 ± 5% and 16 ± 9% of total bradykinin-induced relaxation, and 46 ± 10% and 20 ± 9% of total A23187-induced relaxation, suggesting that NO and PGI2 acted synergistically to cause endothelium-dependent relaxation. 3. Relaxation to low concentrations of acetylcholine was abolished by L-NAME but not affected by indomethacin, suggesting the response was mediated solely by NO with no interaction from PGI2. 4. Glibenclamide (1 μM), an inhibitor of ATP-sensitive potassium (K+A(ATP)) channels, inhibited responses to bradykinin or A23187 but did not affect relaxations evoked by acetylcholine. Glibenclamide did not affect endothelium-independent relaxations to PGI2 or the NO-donor, 3-morpholinosydnonimine (SIN-1). 5. With bradykinin, glibenclamide attenuated total relaxation by 49 ± 8%, but did not alter the individual NO and PGI2-mediated components of the response. Glibenclamide abolished the synergistic interaction between endothelium-derived NO and PGI2. 6. At high concentrations, bradykinin, A23187 or acetylcholine caused endothelium-dependent relaxation that was insensitive to L-NAME + indomethacin. With bradykinin or A23187, this component of relaxation was inhibited by glibenclamide, whereas with acetylcholine, glibenclamide had no effect. 7. The synergistic interaction between endothelium-derived NO and PGI2 in canine pulmonary artery is mediated by activation of K+(ATP) channels, presumably by an endothelium-derived hyperpolarizing factor (EDHF). The pattern of endothelial dilator mediators and the presence of this synergistic interaction is dependent on the nature of the endothelial stimulus.

AB - 1. The aim of the present study was to assess interactions between nitric oxide (NO) and prostacyclin (PGI2) during endothelium-dependent relaxations evoked by bradykinin, calcium ionophore (A23187) and acetylcholine in canine isolated pulmonary artery. 2. Relaxations to low concentrations of bradykinin and A23187 were abolished by combined inhibition of NO-synthase (by N(ω)-nitro-L-arginine methyl ester L-NAME, 30 μM) and cyclo-oxygenase (indomethacin, 10 μM), suggesting mediation by NO and PGI2. The individual contributions of NO and PGI2 to the dilator responses were quantified by use of areas above the separate indomethacin-insensitive and L-NAME-insensitive components of the concentration-effect curves, respectively. Individually, NO and PGI2 accounted for only 53 ± 5% and 16 ± 9% of total bradykinin-induced relaxation, and 46 ± 10% and 20 ± 9% of total A23187-induced relaxation, suggesting that NO and PGI2 acted synergistically to cause endothelium-dependent relaxation. 3. Relaxation to low concentrations of acetylcholine was abolished by L-NAME but not affected by indomethacin, suggesting the response was mediated solely by NO with no interaction from PGI2. 4. Glibenclamide (1 μM), an inhibitor of ATP-sensitive potassium (K+A(ATP)) channels, inhibited responses to bradykinin or A23187 but did not affect relaxations evoked by acetylcholine. Glibenclamide did not affect endothelium-independent relaxations to PGI2 or the NO-donor, 3-morpholinosydnonimine (SIN-1). 5. With bradykinin, glibenclamide attenuated total relaxation by 49 ± 8%, but did not alter the individual NO and PGI2-mediated components of the response. Glibenclamide abolished the synergistic interaction between endothelium-derived NO and PGI2. 6. At high concentrations, bradykinin, A23187 or acetylcholine caused endothelium-dependent relaxation that was insensitive to L-NAME + indomethacin. With bradykinin or A23187, this component of relaxation was inhibited by glibenclamide, whereas with acetylcholine, glibenclamide had no effect. 7. The synergistic interaction between endothelium-derived NO and PGI2 in canine pulmonary artery is mediated by activation of K+(ATP) channels, presumably by an endothelium-derived hyperpolarizing factor (EDHF). The pattern of endothelial dilator mediators and the presence of this synergistic interaction is dependent on the nature of the endothelial stimulus.

KW - A23187

KW - Acetylcholine

KW - Bradykinin

KW - EDHF

KW - Indomethacin

KW - L-NAME

UR - http://www.scopus.com/inward/record.url?scp=0031000110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031000110&partnerID=8YFLogxK

M3 - Article

VL - 121

SP - 271

EP - 279

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -